SureTrader Advertisement PRTC
Home > Boards > US Listed > Biotechs >

Novavax (NVAX)

NVAX RSS Feed
Add NVAX Price Alert      Hide Sticky   Hide Intro
Moderator: LongRun8
Search This Board:
Last Post: 4/13/2016 2:45:46 PM - Followers: 131 - Board type: Free - Posts Today: 0

ABOUT NOVAVAX:

Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biopharmaceutical company creating recombinant protein nanoparticle vaccines to address a broad range of infectious diseases. The company is developing a portfolio of vaccine candidates targeting seasonal and pandemic influenza (H5N1), a vaccine designed to protect children and the elderly against respiratory syncytial virus (RSV), rabies and other candidates. In addition, the company is developing its vaccine candidates for worldwide commercialization including:

Our world-class scientific team is using VLP technology to tackle influenza viruses – including avian strains that have the potential to cause a pandemic outbreak. Our team has created vaccine candidates that are in various phases of clinical testing designed to protect against various circulating strains of pandemic influenza including H1N1 and H5N1, as well as seasonal influenza. Our recombinant nanoparticle protein micelle technology targeted at RSV has been tested in various preclinical studies and has now advanced into clinical testing.

Our vision is to control the spread of infectious diseases by using a unique single-use manufacturing system that allows for the rapid mass production of recombinant protein nanoparticle vaccines. Our goal is to be able to rapidly deliver a customized vaccine in the midst of a declared pandemic.
 


MANAGEMENT TEAM:

President and Chief Executive Officer
Stanley C. Erck

Senior Vice President, Research and Development
Gregory M. Glenn, M.D.

Senior Vice President, Manufacturing and Process Development
Timothy J. Hahn, Ph.D.

Senior Vice President, Chief Financial Officer and Treasurer
Barclay A. "Buck" Phillips

Senior Vice President, Business Development
Russell P. "Rip" Wilson

Vice President, Regulatory Affairs
Amy B. Fix

Vice President, Chief Medical Officer
Louis F. Fries III, M.D.

Vice President, Manufacturing
Mervyn L. Hamer

Vice President, General Counsel and Corporate Secretary
John A. Herrmann III, J.D.

Vice President, Process Development
Erica Shane, Ph.D.

Vice President, Vaccine Development
Gale Smith, Ph.D.

Vice President, Clinical Operations
D. Nigel Thomas, Ph.D.

 

CLINICAL-STAGE PIPELINE:

Novavax’s clinical program includes vaccine candidates designed to address infectious diseases worldwide. Using innovative virus-like particle (VLP) and recombinant nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Our clinical pipeline is shown below.

 
ADJUVANT PIPELINE:

 

 
CHARTS:



 


LINKS:

http://www.novavax.com/
http://finance.yahoo.com/q/h?s=NVAX
http://www.novavax.com/download/File/Interphex.pdf
http://www.sec.gov/cgi-bin/browse-edgar?company=Novavax&CIK=&filenum=&State=&SIC=&owner=include&action=getcompany
http://www.wipo.int/pctdb/en/wo.jsp?WO=2008061243

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NVAX
Current Price
Volume:
Bid Ask Day's Range
SureTrader
NVAX News: Statement of Changes in Beneficial Ownership (4) 05/25/2016 04:43:14 PM
NVAX News: U.S. FDA Grants Fast Track Designation to Novavax' RSV F Vaccine for Older Adults 05/25/2016 08:00:34 AM
NVAX News: U.S. FDA Grants Fast Track Designation to Novavax’ RSV F Vaccine for Older Adults 05/25/2016 08:00:00 AM
NVAX News: Novavax Receives the Tech Council of Maryland's Chairman's Award 05/12/2016 08:30:26 AM
NVAX News: Novavax Receives the Tech Council of Maryland’s Chairman’s Award 05/12/2016 08:30:00 AM
PostSubject
#2258   Congress tells Obama he can get OFF at AVALANCHE06 04/13/16 02:45:45 PM
#2257   Quite possibly. LongRun8 04/12/16 03:30:11 PM
#2256   $1.9Billion for Zika virus asked from Congress by north40000 04/11/16 08:39:09 PM
#2255   $NVAX is Great...Think BIG! MRatt 04/09/16 12:12:27 AM
#2254   Stupid stock henrytrean 04/07/16 02:19:14 PM
#2253   Nice day today ! don estaban 04/06/16 08:16:56 PM
#2252   I believe that volume at close was options expiring. bra1loga 03/21/16 09:15:27 AM
#2251   I picked up 12k shares around 4.70 looking don estaban 03/19/16 12:33:18 PM
#2250   Still here... $NVAX is the Man! MRatt 03/19/16 12:20:28 PM
#2249   Hmmm. That's a lot of volume. LongRun8 03/18/16 06:19:24 PM
#2248   3.5 million buy at 5.07 ?? don estaban 03/18/16 04:21:22 PM
#2247   Yup, still here. Just waiting till Q3. LongRun8 03/15/16 04:23:08 PM
#2246   Anybody here? don estaban 03/14/16 11:52:10 PM
#2245   Movers and Shakers: The Week so Far in nyctraydr 01/26/16 01:57:28 PM
#2244   I have thought about the fact that they LongRun8 01/26/16 09:12:56 AM
#2243   They have plenty of cash, could the funds Tate 01/26/16 08:51:06 AM
#2242   Correct. Must meet the exception. What LongRun8 01/26/16 07:12:22 AM
#2241   That has to do with sale of shares BigBake1 01/26/16 05:57:29 AM
#2240   Update tonight $300M @ NVAX Investor100 01/25/16 10:34:50 PM
#2239   $300 million, up from $200 million offer Novavax Prices LongRun8 01/25/16 09:33:22 PM
#2238   Missed that part... but I would surmise that AVALANCHE06 01/25/16 08:44:20 PM
#2237   Also, only outside the US... "The offer and sale LongRun8 01/25/16 05:26:56 PM
#2236   Says will be sold only to Qualified Institutions.....maybe AVALANCHE06 01/25/16 04:58:29 PM
#2235   Novavax Announces Proposed Offering of $200 Million of Investor100 01/25/16 02:58:30 PM
#2234   CEO @ Mad Money Investor100 01/16/16 12:04:33 PM
#2233   Pure craziness today! I think patient investors LongRun8 01/14/16 10:51:10 PM
#2232   NVAX has the potential to be bought out stockwinner 11/24/15 03:19:37 PM
#2231   153 "contacts" under observation, Reuters reported. north40000 11/23/15 10:43:32 PM
#2230   Geez, just when you thought Ebola was gone. LongRun8 11/23/15 10:39:26 PM
#2229   3 new Ebola cases emerge in Liberia, Reuters north40000 11/23/15 10:22:10 PM
#2228   No new insight. Everything is pretty much LongRun8 11/23/15 10:22:18 AM
#2227   Any new insight here? basssque 11/22/15 11:29:09 AM
#2226   NVAX is enrolling for RSV Ph 3. nypete 11/03/15 06:19:49 PM
#2225   Biotech is on a fire sale. nypete 09/29/15 03:40:33 PM
#2224   It wasn't the reason. It was the excuse. Juice Newton 09/29/15 03:12:19 PM
#2223   Another bogus tweet apparently the reason for initial north40000 09/29/15 09:53:37 AM
#2222   http://ih.advfn.com/p.php?pid=nmona&article=68685359 Stock price down despite this second PR. north40000 09/29/15 09:37:00 AM
#2221   Novavax Announces Grant of Up to $89 Million LongRun8 09/29/15 09:04:05 AM
#2220   Confidential Treatment Order - CTO sarshee 09/27/15 02:25:09 AM
#2219   What the heck is happening here? Does anyone sarshee 09/27/15 02:18:51 AM
#2218   If there was a secondary coming, Stan would underdog150 09/25/15 04:32:29 PM
#2217   There may be a secondary but I doubt Billcoln 09/23/15 11:41:19 PM
#2216   Has anyone looked at the Jan 2018 options owen3838 09/16/15 10:49:47 PM
#2215   We'll see if there's any info that comes VisionsofSugarPlums 09/08/15 01:25:13 PM
#2214   Hopefully we get positive maternity results for NVAX stockwinner 08/19/15 10:36:36 PM
#2213   Looks like NVAX and all bio techs are sarshee 08/19/15 12:27:41 PM
#2212   NVAX: Good interview of CEO by Cramer on north40000 08/12/15 06:26:32 PM
#2211   Yes, the market for RSV is very significant, LongRun8 08/11/15 02:46:47 PM
#2210   Wow, transcript of CC gives lots of reasons Jon32 08/11/15 07:34:54 AM
#2209   Just bought 1300 in after hour $11.80 devilfromscratch 08/10/15 04:32:27 PM
PostSubject